ResearcherRutgers, The State University of New JerseyNo recent work listed
Pat Gulhati
Matched on ORCID iD 0000-0003-2625-313X; OpenAlex author ID A5086998930. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 28
2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper
Papers 3
- Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Co-author DOI 10.1038/s43018-022-00500-z↗
- Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Co-author DOI 10.1158/2159-8290.cd-19-0297↗
- First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6807-9↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Huamin Wang · 3 shared papers, 2019–2023 · strength 0.28
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z↗
- Paper Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenviron… DOI 10.1158/2159-8290.cd-19-0297↗
- Paper First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-018-6807-9↗
- Anirban Maitra · 3 shared papers, 2019–2023 · strength 0.28
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z↗
- Paper Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenviron… DOI 10.1158/2159-8290.cd-19-0297↗
- Paper First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-018-6807-9↗
- Haoqiang Ying · 2 shared papers, 2020–2023 · strength 0.21
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z↗
- Paper Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenviron… DOI 10.1158/2159-8290.cd-19-0297↗
- Ronald Anthony Depinho · 2 shared papers, 2020–2023 · strength 0.21
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z↗
- Paper Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenviron… DOI 10.1158/2159-8290.cd-19-0297↗
- Prasenjit Dey · 2 shared papers, 2020–2023 · strength 0.21
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z↗
- Paper Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenviron… DOI 10.1158/2159-8290.cd-19-0297↗
- Aislyn P. Schalck · 1 shared paper, 2023 · strength 0.13
- Jincheng Han · 1 shared paper, 2023 · strength 0.13
- Pingping Hou · 1 shared paper, 2023 · strength 0.13
- Michael P. Kim · 1 shared paper, 2023 · strength 0.13
- Jianhua Zhang · 1 shared paper, 2020 · strength 0.08
- Giannicola Genovese · 1 shared paper, 2020 · strength 0.08
- Vincent Bernard · 1 shared paper, 2020 · strength 0.08
- Nagireddy Putluri · 1 shared paper, 2020 · strength 0.08
- Bidyut Ghosh · 1 shared paper, 2020 · strength 0.08
- Rachna T. Shroff · 1 shared paper, 2019 · strength 0.08
- Milind M. Javle · 1 shared paper, 2019 · strength 0.08
- Matthew H. G. Katz · 1 shared paper, 2019 · strength 0.08
- Jeffrey H. Lee · 1 shared paper, 2019 · strength 0.08
- Eric Peter Tamm · 1 shared paper, 2019 · strength 0.08
- Robert A. Wolff · 1 shared paper, 2019 · strength 0.08
- Laura R. Prakash · 1 shared paper, 2019 · strength 0.08
- Priya Bhosale · 1 shared paper, 2019 · strength 0.08
- Eugene Jon Koay · 1 shared paper, 2019 · strength 0.08
- Gauri Rajani Varadhachary · 1 shared paper, 2019 · strength 0.08
- David R. Fogelman · 1 shared paper, 2019 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.